Shukra Medtech Reports Zero Deviation in Preferential Issue Fund Utilization
Shukra Pharmaceuticals Ltd · Others (Uncategorized) · 05 Nov 2026, 2:18 am
Shukra Medtech Reports Zero Deviation in Preferential Issue Fund Utilization Shukra Medtech Limited confirmed zero deviation or variation in utilizing funds raised via 46.43 lakh convertible warrants issued on a preferential basis. The company received 75% of the consideration totaling ₹10.46 cr across 14th Jul'26 and 2nd Sep'26. As of the quarter ended 30th Sep'26, the entire ₹10.46 cr proceeds were fully deployed as planned: ₹5.76 cr for working capital and bank guarantee margins, ₹4.23 cr for capex in subsidiary companies, and ₹0.45 cr toward general corporate purposes, with no modifications to original objectives.
Original exchange filing (PDF)
More announcements from Shukra Pharmaceuticals Ltd
- Approval for Change of Name of Company on National Stock Exchange Limited dated 16th November 2026 · 17 Nov 2026
- Media Release · 05 Nov 2026
- Shukra Pharmaceuticals Limited has submitted to the Exchange, the financial results for the period ended September 30, 2026. · 05 Nov 2026
- Unaudited financial results for the quarter ended 30th September 2026 · 05 Nov 2026
- Unaudited financial results for the quarter ended 30th September 2026 · 05 Nov 2026
- SHUKRA PHARMACEUTICALS LIMITED has informed the Exchange about Board Meeting to be held on 04-Nov-2026 to inter-alia consider and approve the Unaudited Financial results of the Company for the Quarterly ended September 2026 . · 04 Nov 2026
- The Board Meeting to be held on 03/11/2026 has been revised to 04/11/2026 The Board Meeting to be held on 03/11/2026 has been revised to 04/11/2026 · 04 Nov 2026
- SHUKRA PHARMACEUTICALS LIMITED has informed the Exchange about Board Meeting to be held on 04-Nov-2026 to inter-alia consider and approve the Unaudited Financial results of the Company for the Quarterly ended September 2026 . · 04 Nov 2026
